Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Suppressor of cytokine signaling 3 (SOCS-3) (Cytokine-inducible SH2 protein 3) (CIS-3) (STAT-induced STAT inhibitor 3) (SSI-3)

 SOCS3_HUMAN             Reviewed;         225 AA.
O14543; O14509;
16-APR-2002, integrated into UniProtKB/Swiss-Prot.
01-JAN-1998, sequence version 1.
22-NOV-2017, entry version 163.
RecName: Full=Suppressor of cytokine signaling 3;
Short=SOCS-3;
AltName: Full=Cytokine-inducible SH2 protein 3;
Short=CIS-3;
AltName: Full=STAT-induced STAT inhibitor 3;
Short=SSI-3;
Name=SOCS3; Synonyms=CIS3, SSI3;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TYR-125.
TISSUE=T-cell lymphoma;
PubMed=9266833; DOI=10.1006/bbrc.1997.7080;
Minamoto S., Ikegame K., Ueno K., Narazaki M., Naka T., Yamamoto H.,
Matsumoto T., Saito H., Hosoe S., Kishimoto T.;
"Cloning and functional analysis of new members of STAT induced STAT
inhibitor (SSI) family: SSI-2 and SSI-3.";
Biochem. Biophys. Res. Commun. 237:79-83(1997).
[2]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=9344848; DOI=10.1006/bbrc.1997.7484;
Masuhara M., Sakamoto H., Matsumoto A., Suzuki R., Yasukawa H.,
Mitsui K., Wakioka T., Tanimura S., Sasaki A., Misawa H., Yokouchi M.,
Ohtsubo M., Yoshimura A.;
"Cloning and characterization of novel CIS family genes.";
Biochem. Biophys. Res. Commun. 239:439-446(1997).
[3]
NUCLEOTIDE SEQUENCE [MRNA].
TISSUE=Skeletal muscle;
PubMed=11071852; DOI=10.1006/bbrc.2000.3762;
Dey B.R., Furlanetto R.W., Nissley P.;
"Suppressor of cytokine signaling (SOCS)-3 protein interacts with the
insulin-like growth factor-I receptor.";
Biochem. Biophys. Res. Commun. 278:38-43(2000).
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=Placenta;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[5]
INTERACTION WITH JAK2, AND MUTAGENESIS OF LEU-22; PHE-25; GLU-30;
TYR-31; VAL-34; LEU-41; GLY-45 AND ARG-71.
PubMed=10421843; DOI=10.1046/j.1365-2443.1999.00263.x;
Sasaki A., Yasukawa H., Suzuki A., Kamizono S., Syoda T., Kinjyo I.,
Sasaki M., Johnston J.A., Yoshimura A.;
"Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine
kinase by binding through the N-terminal kinase inhibitory region as
well as SH2 domain.";
Genes Cells 4:339-351(1999).
[6]
INTERACTION WITH EPOR, AND MUTAGENESIS OF GLY-53; LEU-58; LEU-93 AND
ARG-94.
PubMed=12027890; DOI=10.1046/j.1432-1033.2002.02916.x;
Hoertner M., Nielsch U., Mayr L.M., Heinrich P.C., Haan S.;
"A new high affinity binding site for suppressor of cytokine
signaling-3 on the erythropoietin receptor.";
Eur. J. Biochem. 269:2516-2526(2002).
[7]
INTERACTION WITH IL12RB2, AND MUTAGENESIS OF ARG-71.
PubMed=14559241; DOI=10.1016/j.bbrc.2003.09.140;
Yamamoto K., Yamaguchi M., Miyasaka N., Miura O.;
"SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its
SH2 domain to the STAT4 docking site in the IL-12 receptor beta2
subunit.";
Biochem. Biophys. Res. Commun. 310:1188-1193(2003).
[8]
INTERACTION WITH CSNK1E, AND PROTEIN STABILIZATION.
PubMed=15070676; DOI=10.1182/blood-2003-08-2768;
Okamura A., Iwata N., Nagata A., Tamekane A., Shimoyama M., Gomyo H.,
Yakushijin K., Urahama N., Hamaguchi M., Fukui C., Chihara K., Ito M.,
Matsui T.;
"Involvement of casein kinase Iepsilon in cytokine-induced
granulocytic differentiation.";
Blood 103:2997-3004(2004).
[9]
FUNCTION IN AN E3 UBIQUITIN-PROTEIN LIGASE COMPLEX, AND INTERACTION
WITH CUL5; RNF7; ELOB AND ELOC.
PubMed=15601820; DOI=10.1101/gad.1252404;
Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D.,
Conaway R.C., Conaway J.W., Nakayama K.I.;
"VHL-box and SOCS-box domains determine binding specificity for Cul2-
Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases.";
Genes Dev. 18:3055-3065(2004).
[10]
POSSIBLE INVOLVEMENT IN ATOPIC DERMATITIS.
PubMed=16685656; DOI=10.1086/504272;
Ekelund E., Saeaef A., Tengvall-Linder M., Melen E., Link J.,
Barker J., Reynolds N.J., Meggitt S.J., Kere J., Wahlgren C.-F.,
Pershagen G., Wickman M., Nordenskjoeld M., Kockum I., Bradley M.;
"Elevated expression and genetic association links the SOCS3 gene to
atopic dermatitis.";
Am. J. Hum. Genet. 78:1060-1065(2006).
[11]
INTERACTION WITH FGFR3.
PubMed=16410555; DOI=10.1242/jcs.02740;
Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E.;
"Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with
and modulate fibroblast growth factor receptor signaling.";
J. Cell Sci. 119:380-387(2006).
[12]
INTERACTION WITH NOD2.
PubMed=23019338; DOI=10.1074/jbc.M112.410027;
Lee K.H., Biswas A., Liu Y.J., Kobayashi K.S.;
"Proteasomal degradation of Nod2 protein mediates tolerance to
bacterial cell wall components.";
J. Biol. Chem. 287:39800-39811(2012).
-!- FUNCTION: SOCS family proteins form part of a classical negative
feedback system that regulates cytokine signal transduction. SOCS3
is involved in negative regulation of cytokines that signal
through the JAK/STAT pathway. Inhibits cytokine signal
transduction by binding to tyrosine kinase receptors including
gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin
receptors. Binding to JAK2 inhibits its kinase activity.
Suppresses fetal liver erythropoiesis. Regulates onset and
maintenance of allergic responses mediated by T-helper type 2
cells. Regulates IL-6 signaling in vivo (By similarity). Probable
substrate recognition component of a SCF-like ECS (Elongin BC-
CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which
mediates the ubiquitination and subsequent proteasomal degradation
of target proteins. Seems to recognize IL6ST (By similarity).
{ECO:0000250, ECO:0000269|PubMed:15601820}.
-!- PATHWAY: Protein modification; protein ubiquitination.
-!- SUBUNIT: Interacts with multiple activated proteins of the
tyrosine kinase signaling pathway including IGF1 receptor, insulin
receptor and JAK2. Binding to JAK2 is mediated through the KIR and
SH2 domains to a phosphorylated tyrosine residue within the JAK2
JH1 domain (PubMed:10421843). Binds specific activated tyrosine
residues of the leptin, EPO, IL12, GSCF and gp130 receptors
(PubMed:12027890, PubMed:14559241). Interaction with CSNK1E
stabilizes SOCS3 protein (PubMed:15070676). Component of the
probable ECS(SOCS3) E3 ubiquitin-protein ligase complex which
contains CUL5, RNF7/RBX2, Elongin BC complex and SOCS3
(PubMed:15601820). Interacts with CUL5, RNF7, ELOB and ELOC
(PubMed:15601820). Interacts with CUL2 (PubMed:15601820).
Interacts with FGFR3 (PubMed:16410555). Interacts with INSR (By
similarity). Interacts with BCL10; this interaction may interfere
with BCL10-binding with PELI2 (By similarity). Interacts with NOD2
(via CARD domain); the interaction promotes NOD2 degradation
(PubMed:23019338). {ECO:0000250|UniProtKB:O35718,
ECO:0000269|PubMed:10421843, ECO:0000269|PubMed:12027890,
ECO:0000269|PubMed:14559241, ECO:0000269|PubMed:15070676,
ECO:0000269|PubMed:15601820, ECO:0000269|PubMed:16410555,
ECO:0000269|PubMed:23019338}.
-!- INTERACTION:
Q13480:GAB1; NbExp=4; IntAct=EBI-714146, EBI-517684;
Q8N8K9:KIAA1958; NbExp=5; IntAct=EBI-714146, EBI-10181113;
P10721:KIT; NbExp=3; IntAct=EBI-714146, EBI-1379503;
Q66K74:MAP1S; NbExp=6; IntAct=EBI-714146, EBI-2133734;
I6L996:PTK2; NbExp=3; IntAct=EBI-714146, EBI-10181089;
O95863:SNAI1; NbExp=3; IntAct=EBI-714146, EBI-1045459;
P07947:YES1; NbExp=5; IntAct=EBI-714146, EBI-515331;
-!- TISSUE SPECIFICITY: Widely expressed with high expression in
heart, placenta, skeletal muscle, peripheral blood leukocytes,
fetal and adult lung, and fetal liver and kidney. Lower levels in
thymus.
-!- DOMAIN: The ESS and SH2 domains are required for JAK
phosphotyrosine binding. Further interaction with the KIR domain
is necessary for signal and kinase inhibition.
-!- DOMAIN: The SOCS box domain mediates the interaction with the
Elongin BC complex, an adapter module in different E3 ubiquitin
ligase complexes. {ECO:0000250}.
-!- PTM: Phosphorylated on tyrosine residues after stimulation by the
cytokines, IL-2, EPO or IGF1.
-!- DISEASE: Note=There is some evidence that SOCS3 may be a
susceptibility gene for atopic dermatitis linked to 17q25. SOCS3
messenger RNA is significantly more highly expressed in skin from
patients with atopic dermatitis than in skin from healthy
controls. Furthermore, a genetic association between atopic
dermatitis and a haplotype in the SOCS3 gene has been found in two
independent groups of patients. {ECO:0000269|PubMed:16685656}.
-!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
and Haematology;
URL="http://atlasgeneticsoncology.org/Genes/SOCS3ID44124ch17q25.html";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; AB004904; BAA22430.1; -; mRNA.
EMBL; AB006967; BAA22537.1; -; mRNA.
EMBL; AF159854; AAD42231.1; -; mRNA.
EMBL; BC060858; AAH60858.1; -; mRNA.
CCDS; CCDS11756.1; -.
PIR; JC5627; JC5627.
PIR; JC5761; JC5761.
RefSeq; NP_003946.3; NM_003955.4.
UniGene; Hs.527973; -.
UniGene; Hs.703620; -.
ProteinModelPortal; O14543; -.
BioGrid; 114488; 78.
CORUM; O14543; -.
IntAct; O14543; 37.
MINT; MINT-149732; -.
STRING; 9606.ENSP00000330341; -.
iPTMnet; O14543; -.
PhosphoSitePlus; O14543; -.
PaxDb; O14543; -.
PeptideAtlas; O14543; -.
PRIDE; O14543; -.
DNASU; 9021; -.
Ensembl; ENST00000330871; ENSP00000330341; ENSG00000184557.
GeneID; 9021; -.
KEGG; hsa:9021; -.
CTD; 9021; -.
DisGeNET; 9021; -.
EuPathDB; HostDB:ENSG00000184557.4; -.
GeneCards; SOCS3; -.
HGNC; HGNC:19391; SOCS3.
HPA; CAB012220; -.
HPA; HPA068569; -.
MIM; 604176; gene.
neXtProt; NX_O14543; -.
OpenTargets; ENSG00000184557; -.
PharmGKB; PA134885765; -.
eggNOG; KOG4566; Eukaryota.
eggNOG; ENOG4111V4J; LUCA.
GeneTree; ENSGT00760000119136; -.
HOGENOM; HOG000236320; -.
HOVERGEN; HBG105645; -.
InParanoid; O14543; -.
KO; K04696; -.
OMA; KRTYYIY; -.
OrthoDB; EOG091G0NEU; -.
PhylomeDB; O14543; -.
TreeFam; TF321368; -.
Reactome; R-HSA-2586552; Signaling by Leptin.
Reactome; R-HSA-6783589; Interleukin-6 family signaling.
Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
Reactome; R-HSA-877300; Interferon gamma signaling.
Reactome; R-HSA-877312; Regulation of IFNG signaling.
Reactome; R-HSA-8849474; PTK6 Activates STAT3.
Reactome; R-HSA-8939242; RUNX1 regulates transcription of genes involved in differentiation of keratinocytes.
Reactome; R-HSA-8951664; Neddylation.
Reactome; R-HSA-909733; Interferon alpha/beta signaling.
Reactome; R-HSA-912694; Regulation of IFNA signaling.
Reactome; R-HSA-982772; Growth hormone receptor signaling.
Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
SignaLink; O14543; -.
SIGNOR; O14543; -.
UniPathway; UPA00143; -.
ChiTaRS; SOCS3; human.
GeneWiki; SOCS3; -.
GenomeRNAi; 9021; -.
PRO; PR:O14543; -.
Proteomes; UP000005640; Chromosome 17.
Bgee; ENSG00000184557; -.
CleanEx; HS_SOCS3; -.
ExpressionAtlas; O14543; baseline and differential.
Genevisible; O14543; HS.
GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
GO; GO:0005829; C:cytosol; TAS:Reactome.
GO; GO:0001784; F:phosphotyrosine residue binding; IEA:Ensembl.
GO; GO:0004860; F:protein kinase inhibitor activity; TAS:ProtInc.
GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; IEA:Ensembl.
GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
GO; GO:0007259; P:JAK-STAT cascade; IEA:InterPro.
GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IBA:GO_Central.
GO; GO:0046426; P:negative regulation of JAK-STAT cascade; IMP:BHF-UCL.
GO; GO:0042532; P:negative regulation of tyrosine phosphorylation of STAT protein; IMP:BHF-UCL.
GO; GO:0060674; P:placenta blood vessel development; IEA:Ensembl.
GO; GO:0045597; P:positive regulation of cell differentiation; IEA:Ensembl.
GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; TAS:Reactome.
GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
GO; GO:0040008; P:regulation of growth; IEA:UniProtKB-KW.
GO; GO:0060334; P:regulation of interferon-gamma-mediated signaling pathway; TAS:Reactome.
GO; GO:0060708; P:spongiotrophoblast differentiation; IEA:Ensembl.
GO; GO:0060707; P:trophoblast giant cell differentiation; IEA:Ensembl.
CDD; cd10384; SH2_SOCS3; 1.
Gene3D; 3.30.505.10; -; 1.
InterPro; IPR000980; SH2.
InterPro; IPR036860; SH2_dom_sf.
InterPro; IPR028414; SOCS3.
InterPro; IPR035863; SOCS3_SH2.
InterPro; IPR001496; SOCS_box.
InterPro; IPR036036; SOCS_box-like_dom_sf.
PANTHER; PTHR44534; PTHR44534; 1.
Pfam; PF00017; SH2; 1.
Pfam; PF07525; SOCS_box; 1.
SMART; SM00252; SH2; 1.
SMART; SM00253; SOCS; 1.
SMART; SM00969; SOCS_box; 1.
SUPFAM; SSF158235; SSF158235; 1.
SUPFAM; SSF55550; SSF55550; 1.
PROSITE; PS50001; SH2; 1.
PROSITE; PS50225; SOCS; 1.
1: Evidence at protein level;
Complete proteome; Growth regulation; Pharmaceutical; Phosphoprotein;
Polymorphism; Reference proteome; SH2 domain;
Signal transduction inhibitor; Ubl conjugation pathway.
CHAIN 1 225 Suppressor of cytokine signaling 3.
/FTId=PRO_0000181243.
DOMAIN 46 142 SH2. {ECO:0000255|PROSITE-
ProRule:PRU00191}.
DOMAIN 177 224 SOCS box. {ECO:0000255|PROSITE-
ProRule:PRU00194}.
REGION 22 33 Kinase inhibitory region (KIR).
REGION 34 45 Extended SH2 subdomain (ESS).
VARIANT 125 125 H -> Y (in dbSNP:rs1061489).
{ECO:0000269|PubMed:9266833}.
/FTId=VAR_030033.
MUTAGEN 22 22 L->A,F: Little effect on EPO-induced
STAT5 signaling suppression.
{ECO:0000269|PubMed:10421843}.
MUTAGEN 22 22 L->D: Complete loss of EPO-induced STAT5
signaling suppression. No suppression of
JAK2 phosphorylation.
{ECO:0000269|PubMed:10421843}.
MUTAGEN 25 25 F->A: Complete loss of EPO-induced STAT5
signaling suppression. Abolishes binding
to JH1. {ECO:0000269|PubMed:10421843}.
MUTAGEN 30 30 E->R: Partial loss of EPO-induced STAT5
signaling suppression. No effect on LIF-
induced signaling suppression. Abolishes
binding to JH1. Inhibits JAK2
phosphorylation.
{ECO:0000269|PubMed:10421843}.
MUTAGEN 31 31 Y->A: Complete loss of EPO-induced STAT5
signaling suppression. No effect on LIF-
induced STAT3 signaling. Abolishes
binding to JH1.
{ECO:0000269|PubMed:10421843}.
MUTAGEN 31 31 Y->F: Little effect on EPO-induced
signaling suppression.
{ECO:0000269|PubMed:10421843}.
MUTAGEN 34 34 V->E: Complete loss of EPO/LIF-induced
signaling suppression.
{ECO:0000269|PubMed:10421843}.
MUTAGEN 41 41 L->R: Complete loss of EPO/LIF-induced
signaling inhibition. Abolishes binding
to JH1. {ECO:0000269|PubMed:10421843}.
MUTAGEN 45 45 G->A: Little effect on EPO/LIF signaling.
{ECO:0000269|PubMed:10421843}.
MUTAGEN 53 53 G->V: No effect on binding to Y429/Y431
phosphorylated EPOR.
{ECO:0000269|PubMed:12027890}.
MUTAGEN 58 58 L->A: Impaired binding to Y429/Y431
phosphorylated EPOR.
{ECO:0000269|PubMed:12027890}.
MUTAGEN 71 71 R->E: Complete loss of EPO/LIF-induced
signaling suppression. No inhibition of
JAK2 phosphorylation.
{ECO:0000269|PubMed:10421843,
ECO:0000269|PubMed:14559241}.
MUTAGEN 71 71 R->K: No effect on EPO/LIF-induced
signaling suppression. Partial
suppression of JAK2 phosphorylation. No
effect on binding to JH1. Loss of binding
to IL12RB2. {ECO:0000269|PubMed:10421843,
ECO:0000269|PubMed:14559241}.
MUTAGEN 93 93 L->A: Impaired binding to Y429/Y431
phosphorylated EPOR.
{ECO:0000269|PubMed:12027890}.
MUTAGEN 94 94 R->E: Greatly impaired binding to
Y429/Y431 phosphorylated EPOR.
{ECO:0000269|PubMed:12027890}.
CONFLICT 81 81 T -> A (in Ref. 1; BAA22430).
{ECO:0000305}.
SEQUENCE 225 AA; 24770 MW; 08581DC411EFFF19 CRC64;
MVTHSKFPAA GMSRPLDTSL RLKTFSSKSE YQLVVNAVRK LQESGFYWSA VTGGEANLLL
SAEPAGTFLI RDSSDQRHFF TLSVKTQSGT KNLRIQCEGG SFSLQSDPRS TQPVPRFDCV
LKLVHHYMPP PGAPSFPSPP TEPSSEVPEQ PSAQPLPGSP PRRAYYIYSG GEKIPLVLSR
PLSSNVATLQ HLCRKTVNGH LDSYEKVTQL PGPIREFLDQ YDAPL


Related products :

Catalog number Product name Quantity
EIAAB39195 CIS2,CIS-2,Cytokine-inducible SH2 protein 2,Homo sapiens,Human,SOCS2,SOCS-2,SSI2,SSI-2,STATI2,STAT-induced STAT inhibitor 2,Suppressor of cytokine signaling 2
E1684h ELISA kit CIS3,CIS-3,Cytokine-inducible SH2 protein 3,Homo sapiens,Human,SOCS3,SOCS-3,SSI3,SSI-3,STAT-induced STAT inhibitor 3,Suppressor of cytokine signaling 3 96T
U1684h CLIA CIS3,CIS-3,Cytokine-inducible SH2 protein 3,Homo sapiens,Human,SOCS3,SOCS-3,SSI3,SSI-3,STAT-induced STAT inhibitor 3,Suppressor of cytokine signaling 3 96T
E1684h ELISA CIS3,CIS-3,Cytokine-inducible SH2 protein 3,Homo sapiens,Human,SOCS3,SOCS-3,SSI3,SSI-3,STAT-induced STAT inhibitor 3,Suppressor of cytokine signaling 3 96T
29-704 SOCS1 is a member of the STAT-induced STAT inhibitor (SSI), also known as suppressor of cytokine signaling (SOCS), family. SSI family members are cytokine-inducible negative regulators of cytokine sig 0.1 mg
EIAAB39188 Cish1,JAB,JAK-binding protein,Mouse,Mus musculus,Socs1,SOCS-1,Ssi1,SSI-1,STAT-induced STAT inhibitor 1,Suppressor of cytokine signaling 1
18-003-43725 Suppressor of cytokine signaling 1 - SOCS-1; JAK-binding protein; JAB; STAT-induced STAT inhibitor 1; SSI-1; Tec-interacting protein 3; TIP-3 Polyclonal 0.1 mg Protein A
EIAAB39190 Homo sapiens,Human,JAB,JAK-binding protein,SOCS1,SOCS-1,SSI1,SSI-1,STAT-induced STAT inhibitor 1,Suppressor of cytokine signaling 1,Tec-interacting protein 3,TIP3,TIP-3
18-783-75581 RABBIT ANTI SOCS 1 (N-TERMINAL) - SUPPRESSOR OF CYTOKINE SIGNALLING 1; SOCS-1; JAK-binding protein; JAB; STAT-induced STAT inhibitor 1; SSI-1; Tec-interacting protein 3; TIP-3 Polyclonal 0.1 mg
18-783-75587 RABBIT ANTI SOCS 1 (C-TERMINAL) - SUPPRESSOR OF CYTOKINE SIGNALLING 1; SOCS-1; JAK-binding protein; JAB; STAT-induced STAT inhibitor 1; SSI-1; Tec-interacting protein 3; TIP-3 Polyclonal 0.1 mg
EIAAB39202 CIS4,CIS-4,Cytokine-inducible SH2 protein 4,Homo sapiens,Human,SOCS4,SOCS-4,SOCS6,SOCS-6,Suppressor of cytokine signaling 4,Suppressor of cytokine signaling 6
EIAAB39203 Cis4,CIS-4,Cish4,Cytokine-inducible SH2 protein 4,Mouse,Mus musculus,Socs4,SOCS-4,Socs6,SOCS-6,Suppressor of cytokine signaling 4,Suppressor of cytokine signaling 6
EIAAB39201 CIS6,CIS-6,CISH5,CISH6,Cytokine-inducible SH2 protein 6,Cytokine-inducible SH2-containing protein 5,Homo sapiens,Human,KIAA0671,SOCS5,SOCS-5,Suppressor of cytokine signaling 5
EIAAB07443 CIS,CIS-1,Cish,Cytokine-inducible SH2-containing protein,Rat,Rattus norvegicus,SOCS,Suppressor of cytokine signaling
EIAAB07442 CIS,Cis,CIS-1,Cish,Cytokine-inducible SH2-containing protein,Mouse,Mus musculus,SOCS,Suppressor of cytokine signaling
EIAAB39200 Cish5,Cytokine-inducible SH2-containing protein 5,Mouse,Mus musculus,Socs5,SOCS-5,Suppressor of cytokine signaling 5
EIAAB39191 Cish2,Cytokine-inducible SH2 protein 2,Rat,Rattus norvegicus,Socs2,SOCS-2,Suppressor of cytokine signaling 2
E1684r ELISA Cish3,Cytokine-inducible SH2 protein 3,Rat,Rattus norvegicus,Socs3,SOCS-3,Suppressor of cytokine signaling 3 96T
U1684r CLIA Cish3,Cytokine-inducible SH2 protein 3,Rat,Rattus norvegicus,Socs3,SOCS-3,Suppressor of cytokine signaling 3 96T
E1684r ELISA kit Cish3,Cytokine-inducible SH2 protein 3,Rat,Rattus norvegicus,Socs3,SOCS-3,Suppressor of cytokine signaling 3 96T
EIAAB39193 Cis2,CIS-2,Cish2,Cytokine-inducible SH2 protein 2,Mouse,Mus musculus,Socs2,SOCS-2,Suppressor of cytokine signaling 2
EIAAB07441 CIS,CIS-1,CISH,Cytokine-inducible SH2-containing protein,G18,Homo sapiens,Human,Protein G18,SOCS,Suppressor of cytokine signaling
E1684m ELISA kit Cis3,CIS-3,Cish3,Cytokine-inducible SH2 protein 3,Mouse,Mus musculus,Protein EF-10,Socs3,SOCS-3,Suppressor of cytokine signaling 3 96T
E1684m ELISA Cis3,CIS-3,Cish3,Cytokine-inducible SH2 protein 3,Mouse,Mus musculus,Protein EF-10,Socs3,SOCS-3,Suppressor of cytokine signaling 3 96T
U1684m CLIA Cis3,CIS-3,Cish3,Cytokine-inducible SH2 protein 3,Mouse,Mus musculus,Protein EF-10,Socs3,SOCS-3,Suppressor of cytokine signaling 3 96T


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur